8 May, 2016 by The TZ Newswire Staff Comments Off on Does big data have a discrimination problem? Some say…maybe
Does big data have a discrimination problem? Some say…maybe
Critics of big data say machine learning systems can be biased.
8 May, 2016 by The TZ Newswire Staff Comments Off on Saudi Arabia fires longtime oil minister
Saudi Arabia fires longtime oil minister
Ali al-Naimi, the most powerful man in the oil business for two decades, is out of a job.
8 May, 2016 by The TZ Newswire Staff Comments Off on Why Citi Is Worried: "This Is The Tipping Point"
Why Citi Is Worried: "This Is The Tipping Point"
In his latest must read presentation, Citigroup’s Matt King continues to expose – and be very concerned by – the increasing helplessness (and cluelessness) of central bankers, something this website has done since 2009, fully aware how it all ends.
8 May, 2016 by The TZ Newswire Staff Comments Off on Is this American Funds Money Market Fund Worth It? (AFAXX)
Is this American Funds Money Market Fund Worth It? (AFAXX)
Discover why the American Funds U.S. Government Money Market Fund’s high expenses and 0% yield make it a less-than-ideal choice for most investors.
8 May, 2016 by The TZ Newswire Staff Comments Off on This Is What Fueled Apache Corporation’s 14.5% Rally in April
This Is What Fueled Apache Corporation’s 14.5% Rally in April
Image source: Apache Corporation.
What: Shares of Apache (NYSE: APA) jumped double digits in April on the back of a rally in the crude oil market and some praise from the analyst community.
8 May, 2016 by The TZ Newswire Staff Comments Off on GOP elite run for cover as ‘Trump train’ barrels down tracks
GOP elite run for cover as ‘Trump train’ barrels down tracks
Donald J. Trump’s hostile takeover of the GOP has the party’s elite fearing an epochal split, The New York Times reports.
8 May, 2016 by The TZ Newswire Staff Comments Off on The Revolutionary Multiple Sclerosis Drug You’ve Never Heard Of
The Revolutionary Multiple Sclerosis Drug You’ve Never Heard Of
Image source: Roche.
A bunch of new, expensive, and incrementally better multiple sclerosis therapies approved over the past decade sent global spending on such drugs skyrocketing to nearly $20 billion last year.
Those of you that understand this awful disease will be glad to learn Roche (NASDAQOTH: RHHBY) has a drug on deck that could send all those rookies back to the minor leagues.